Financial Metrics Compare Agios Pharmaceuticals and Incyte
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
A comparison of Agios Pharmaceuticals and Incyte examined several financial metrics, including volatility, institutional ownership, and analyst ratings. Agios Pharmaceuticals has a beta of 0.63, while Incyte has a beta of 0.74. According to the report, equities research analysts believe Agios Pharmaceuticals is more favorable than Incyte due to its stronger consensus rating and higher probable upside of 33.60% compared to Incyte's 11.67% upside.
From dailypolitical.com
Why it matters
The comparison provides insight into the risk profiles and market sentiment surrounding the two pharmaceutical companies. Differences in institutional and insider ownership suggest varying levels of confidence from large money managers and company insiders regarding future performance.
From dailypolitical.com
Who's involved
- Agios PharmaceuticalsA public American pharmaceutical company whose financial metrics were compared.
- IncyteAn American pharmaceutical company that is a direct competitor to Agios Pharmaceuticals.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Agios PharmaceuticalsSpeculative
Agios Pharmaceuticals might see changes in investment funding based on the favorable consensus rating reported.
- IncyteSpeculative
Incyte could face changes in demand for its stock if investors shift preference toward the company with the higher probable upside.
Keep exploring
The entities involved
-
Agios Pharmaceuticals
a public American pharmaceutical company
Nothing else this week.
-
Incyte
American pharmaceutical company